The report argued that the standard of proof for usefulness in Canadian law is not onerous and that the standard is “easily met, as long as the patent is soundly based in science and not speculative in nature.” “The pharmaceutical industry suggests that the Canadian approach will undermine pharmaceutical investment,” the report says.